ArticleJournal of computer-aided molecular design2025
Novel insight into CFTR gene's single nucleotide variants classification via in-silico analysis of a conserved site.
Article in Journal of computer-aided molecular design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutations in the CFTR gene play a pivotal role in the onset/severity of cystic fibrosis (CF). While our understanding of CFTR mutation classes is fragmented, this study focused on missense single nucleotide variants (SNVs) in the ABC transporter-like conserved site of the CFTR protein, employing various bioinformatics tools to identify deleterious amino acid substitutions (A.A.S). To gain a comparative understanding of the deleterious A.A.S in CFTR mutation classes, the in silico prediction of classified A.A.S by MutPred2 was cross-referenced with predictions of unclassified A.A.S. The study revealed twenty-five deleterious A.A.S in the conserved site. Nine of these (S549R, S549N, G551S, G551D, L558S, A559T, R560T, R560S, and A561E) were already classified. The in silico predictions for the remaining sixteen A.A.S exhibited similarities to molecular variations predicted for classified CFTR mutations and identified nine A.A.S falling under class II and seven A.A.S falling under class III, while four of these A.A.S in this conserved site may have effects of class II and III mutations. However, this classification is relative, warranting a comprehensive analysis to elucidate the intricacies of these nsSNVs. The combined use of modulators in therapy holds promise for more effective CF management, recognizing that CFTR mutations may exert effects that extend beyond a single class of mutation.
Indexed as
Identifiers
41331145What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.